Oncotarget has been one of the prime journals on Oncology. It is a multi-disciplinary free-access journal which publishes weekly issues of scientific papers online. However, the author or the subscriber has the option of getting a particular report or a paper printed on special demand. There are significant features of the journal that will include:
The mission of the journal is manifold; Oncotarget focuses on easy and wide access scientific results that will be shared amongst peers. It has set up a highly efficient review board which functions to scrutinize and maximize the effect of the research conducted. The journal also aims at bridging several areas of biomedical sciences and promotes the application of basic and clinical sciences for therapeutic outcomes. This will help the scientific community to achieve their ultimate goal of Life without diseases.
Experienced Editorial Board
The journal takes pride in having eminent names on its editorial board. The editor-in-chief is Dr. Andrei V. Gudkov and Dr. Mikhail Blagosklonny of the Roswell Park Cancer Institute. The other eminent members will include Nobel laureate, Dr. Andrew Schally, and Dr. Carlo M. Croce. Four members of Oncotarget has received the prestigious Breakthrough Prize since 2013. Oncotarget is also available on Dove Press.
Impact Factor and high-Index
Since its inclusion in the scientific community in 2010, its growth has been increasing to this day. The journal has a high impact factor of 5.008 with an average impact factor of 5.415 in 2015-16. The total number of citation from this journal has crossed the 10,000 mark and the value currently stands at 10,452. The journal has also received a Scopus/SJR ranking of Q1 since 2011. Another notable achievement for the journal is that it is ranked at the top amongst all journals in oncology by Total Documents.
All these attributes have made Oncotarget one of the most prestigious journals in the field of Oncology. Oncotarget, which is published by Impact Journals